Khoury Tawfik, Tzukert Keren, Abel Roy, Abu Rmeileh Ayman, Levi Ronen, Ilan Yaron
Department of Medicine, Gastroenterology and Liver Units, Jerusalem, Israel.
Department of Nephrology, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.
Hemodial Int. 2017 Jul;21(3):323-334. doi: 10.1111/hdi.12486. Epub 2016 Sep 16.
Evidence is accumulating to consider the gut microbiome as a central player in the gut-kidney axis. Microbiome products, such as advanced glycation end products, phenols, and indoles, are absorbed into the circulation but are cleared by normal-functioning kidneys. These products then become toxic and contribute to the uremic load and to the progression of chronic kidney failure. In this review, we discuss the gut-kidney interaction under the state of chronic kidney failure as well as the potential mechanisms by which a change in the gut flora (termed gut dysbiosis) in chronic kidney disease (CKD) exacerbates uremia and leads to further progression of CKD and inflammation. Finally, the potential therapeutic interventions to target the gut microbiome in CKD are discussed.
越来越多的证据表明,肠道微生物群是肠-肾轴的核心参与者。微生物群产物,如晚期糖基化终产物、酚类和吲哚,会被吸收进入循环系统,但会被功能正常的肾脏清除。这些产物随后会变得有毒,并导致尿毒症负荷增加以及慢性肾衰竭的进展。在这篇综述中,我们讨论了慢性肾衰竭状态下的肠-肾相互作用,以及慢性肾脏病(CKD)中肠道菌群变化(称为肠道生态失调)加剧尿毒症并导致CKD和炎症进一步进展的潜在机制。最后,我们讨论了针对CKD中肠道微生物群的潜在治疗干预措施。